MHLW Approves Rakuten’s Photoimmunotherapy, Takeda’s PARP Inhibitor, Gilead’s Jyseleca and More

September 28, 2020
The Ministry of Health, Labor and Welfare (MHLW) on September 25 granted approval for a batch of new medicines and indications including Rakuten Medical’s antibody drug conjugate (ADC) Akalux (cetuximab sarotalocan sodium), which works on the company’s unique “photoimmunotherapy” platform,...read more